Interferon Beta-1B Dosage
This dosage information may not include all the information needed to use Interferon Beta-1B safely and effectively. See additional information for Interferon Beta-1B.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Multiple Sclerosis
Initial: 0.0625 mg subcutaneously every other day, and increased (by 25% increments) every 2 weeks, over a 6 week period, to maintenance dose
Maintenance: 0.25 mg subcutaneously every other day
Usual Adult Dose for Colorectal Cancer
Phase II trials - advanced colorectal carcinoma (n=81)
9 million international units subcutaneously on days 1, 3, and 5, thereafter 3 times a week (in combination with fluorouracil)
Usual Pediatric Dose for Chronic Inflammatory Demyelinating Polyradiculoneuropathy
1.5 million international units subcutaneously twice a week for 1 week, then 3 million international units 3 times a week
Usual Pediatric Dose for Multiple Sclerosis
Greater than 8.5 years: 8 million international units (0.25 mg) subcutaneously every other day
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Interferon beta-1b should be administered with caution in patients with depression, a condition that is common in people with multiple sclerosis. Depression and suicide have been reported to occur with increased frequency in patients receiving interferon compounds, including interferon beta-1b. Patients should be advised to report immediately to their doctors any symptoms of depression and/or suicidal ideation. If a patient develops depression, discontinuation of interferon beta-1b therapy should be considered.
Injection site necrosis has been reported in controlled trials. Usually, it occurs within the first 4 months of therapy, although injection site necrosis occurring over 1 year after initiation of therapy has been reported during postmarketing experience. For some lesions, debridement and, infrequently, skin grafting have been necessary. As with any open lesion, it is important to avoid infection and to treat it, if infection occurs. Some patients have experienced healing of necrotic skin lesions while interferon beta-1b treatment continued; others have not. Whether to discontinue interferon beta-1b therapy following a single site of necrosis is dependent on the extent of necrosis. For patients who continue treatment with interferon beta-1b after injection site necrosis has occurred, interferon beta-1b should not be administered into the affected area until it is fully healed. If multiple lesions occur, treatment should be discontinued until healing occurs. Aseptic self-injection techniques and procedures should be periodically reevaluated, particularly if injection site necrosis has occurred.
Immediate medical attention is recommended if anaphylaxis or symptoms of an allergic reaction occur with interferon beta-1b administration.
Leukopenia, elevated SGPT (to greater than five times baseline values), and elevated SGOT (to greater than five times baseline values) have been reported in patients receiving interferon beta-1b during controlled trials. In some patients, leukopenia led to dose reduction and elevations in SGPT and SGOT lead to dose reduction or treatment discontinuation. In addition to the laboratory tests normally required for monitoring patients with multiple sclerosis, complete blood and differential white blood cell counts, platelet counts, and blood chemistries, including liver function tests, are recommended at regular intervals (1, 3, and 6 months) following initiation of interferon beta-1b therapy, and then periodically thereafter in the absence of clinical symptoms. Patients with myelosuppression may require more intensive monitoring of complete blood cell counts, with differential and platelet counts.
Thyroid function tests are recommended every 6 months in patients with a history of thyroid dysfunction or as clinically indicated. Close monitoring is recommended due to the many immunologic abnormalities associated with multiple sclerosis.
Clinical trials of interferon beta-1b did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger patients.
Safety and efficacy have not been established in pediatric patients (less than 18 years of age).
Data not available
Pretreatment with analgesics/antipyretics may ameliorate the flu-like symptoms on treatment days. Also, a study (n=71) suggests that the use oral low-dose steroids at the start of treatment lessens the incidence and severity of flu-like symptoms for the first 2 weeks of treatment.